Colchicine biotransformation by human liver microsomes

Biochemical Pharmacology

Volumn 53, Issue 1, 1997, Pages 111-116

  Tateishi, Tomonori ^a,b   Soucek, Pavel ^a,c   Caraco, Yoseph ^a,d   Peter Gnengerich, F ^a   Wood, Alastair J J ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

^d HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

colchicine; CYP3A4; cytochrome P450; drug interaction; drug metabolism

Indexed keywords

2 NORCOLCHICINE; 3 NORCOLCHICINE; BUFURALOL; CHLORZOXAZONE; COLCHICINE; COUMARIN; CYTOCHROME P450 ISOENZYME; DIETHYLDITHIOCARBAMIC ACID; DRUG METABOLITE; ENZYME ANTIBODY; ERYTHROMYCIN; ETHOXYRESORUFIN; GESTODENE; IMMUNOGLOBULIN G; MEPHENYTOIN; NIFEDIPINE; QUINIDINE; RADIOISOTOPE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SULFAPHENAZOLE; TROLEANDOMYCIN; UNCLASSIFIED DRUG;

ARTICLE; BIOTRANSFORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEMETHYLATION; DRUG DISPOSITION; ENZYME SUBSTRATE; HUMAN; HUMAN TISSUE; LIVER MICROSOME; PRIORITY JOURNAL;

COLCHICINE; CYTOCHROME P-450 ENZYME SYSTEM; GOUT SUPPRESSANTS; HUMANS; MICROSOMES, LIVER;

EID: 0031060641     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(96)00693-4     Document Type: Article

References (25)

1. Wallace SL, Colchicine. Semin Arthritis Rheum 3: 369-381, 1974.
2. Levy M and Eliakim M, Long-term colchicine prophylaxis in familial Mediterranean fever. Br Med J 2: 808-809, 1977.
3. Tafi L, Matucci-Cerinic M, Falcini F, Valentini G and Bartolozzi G, Colchicine treatment of Behçet's disease in children. Arthritis Rheum 30: 1435, 1987.
4. Kaplan MM, Ailing DW, Zimmerman HJ, Wolfe HJ, Sepersky RA, Hirsch GS, Elta GH, Glick KA and Eagen KA, A prospective trial of colchicine for primary biliary cirrhosis. N Engl J Med 315: 1448-1454, 1986.
5. Krehennobich D, Vargas F, Garcia-Tsao G, Tamayo RP, Gent M and Rojkind M, Colchicine in the treatment of cirrhosis of the liver. N Engl J Med 318: 1709-1713, 1988.
6. Alarcon-Segovia D, Ramos-Niembro F, de Kasep GI, Alcacer J and Perez Tamayo R, Long term evaluation of colchicine in the treatment of scleroderma. J Rheumatol 6: 705-712, 1979.
7. Ravid M, Robson M and Kedar I, Prolonged colchicine treatment in four patients with amyloidosis. Ann Intern Med 87: 568-570, 1977.
8. Levy M, Spino M and Read SE, Colchicine: A state of the art review. Pharmacotherapy 11: 196-211, 1991.
9. Hunter AL and Klassen CD, Biliary excretion of colchicine. J Pharmacol Exp Ther 192: 605-617, 1974.
10. Sabouraud A, Cano N and Scherrmann JM, Radioimmunoassay of colchicine with antisera exhibiting variable cross-reactivity. Ther Drug Monit 16: 179-185, 1994.
11. Caraco Y, Putterman C, Rahamimov R and Ben-chetrit E, Acute colchicine intoxication - Possible role of erythromycin administration. J Rheumatol 19: 494-496, 1992.
12. Wang PP, Beaune P, Kaminsky LS, Dannan GA, Kadlubar FF, Larrey D and Guengerich FP, Purification and characterization of six cytochrome P-450 isoenzymes from human liver microsomes. Biochemistry 22: 5375-5383, 1983.
13. Omura T and Sato R, The carbon monoxide-binding pigment of liver microsomes. I. Evidence of its hemoprotein nature. J Biol Chem 239: 2370-2378, 1964.
14. Guengerich FP, Mechanism-based inactivation on human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chem Res Toxicol 3: 363-371, 1990.
15. Davis PJ and Klein AE, High-performance liquid Chromatographic separation of colchicine and its phenolic and Ndesacetylated derivatives. J Chromatogr 188: 280-284, 1980.
16. Sabouraud A, Rochdi M, Urtizberea M, Christen MO, Achtert G, Schermann JM, Pharmacokinetics of colchicine: A review of experimental and clinical data. Z Gastroenterol 30 (Suppl 1): 35-39, 1992.
17. Speeg KV, Maldonado AL, Liaci J and Muirhead D, Effect of cyclosporine on colchicine secretion by a liver canalicular transporter studied in vivo. Hepatology 15: 899-903, 1992.
18. Speeg KV, Maldonado AL, Liaci J and Muirhead D, Effect of cyclosporine on colchicine secretion by the kidney multidrug transporter studies in vivo. J Pharmacol Exp Ther 261: 50-55, 1992.
19. Rudi J, Raedsch R, Gerteis C, Schlenker T, Plachky J, Walter-Sack I, Sabouraud A, Scherrmann JM and Kommerell B, Plasma kinetics and biliary excretion of colchicine in patients with chronic liver disease after oral administration of a single dose and after long term treatment. Scand J Gastroenterol 29: 346-351, 1994.
20. Schonharting M, Mende G and Siebert G, The metabolism of colchicine by mammalian liver microsomes. Hoppe-Seylers Z Physiol Chem 355: 1391-1399, 1974.
21. Putterman C, Be-chetrit E, Caraco Y and Levy M, Colchicine intoxication: Clinical pharmacology, risk factors, features and management. Semin Arthritis Rheum 21: 143-155, 1991.
22. Sugio K, Maruyama M, Tsurufuji S, Sharma PN and Brossi A, Separation of tubulin-binding and anti-inflammatory activity in colchicine analogs and congeners. Life Sci 40: 35-39, 1987.
23. Brossi A, Bioactive alkaloids. 4. Results of recent investigations with colchicine and physostigmine. J Med Chem 33: 2311-2319, 1990.
24. Eliakim M, Levy M, Ehrenfeld M (Eds.), Recurrent Polyserositis (Familial Mediterranean Fever, Periodic Disease). Elsevier/ North-Holland Biomedical Press, Amsterdam, Netherlands, 1981.
25. Zemer D, Pras M, Sohar E, Modan M, Cabili S and Gafni J, Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 314: 10011005, 1986.